These target different layers. GHK-Cu is surface-focused: skin, hair, extracellular matrix. BPC-157 is deep-tissue: tendon, ligament, gut. Many users run both, and they appear together in healing stacks.
| GHK-Cu | BPC-157 | |
|---|---|---|
| Class | Copper-binding tripeptide | Gastric pentadecapeptide (15 amino acids) |
| Half-life | Approximately 0.5–1 hour systemically | Oral form ~4 hours; subcutaneous estimated 4–6 hours |
| Typical dose | 1–3 mg per injection; topical concentrations vary | 200–500 mcg per injection, 1–2x daily |
| Category | Skin / connective tissue | Healing / tissue repair |
| FDA status | Used in cosmetic formulations (topical). Not FDA approved as an injectable drug. | Not FDA approved. Research use only in the US. Removed from FDA 503A bulks list in 2023. |
| Storage | Lyophilized refrigerated. | Lyophilized: room temp (stable, short term) or refrigerated. |
Both are research peptides studied for tissue repair and connective-tissue signaling. Neither is FDA approved for human use. Both have reasonable preclinical evidence and limited human data.
Pick GHK-Cu for surface-tissue goals — skin quality, hair follicle support, wound healing at or near the skin surface, hair-line topical protocols. GHK-Cu also has the best evidence for gene-expression modulation related to regenerative signaling.
Pick BPC-157 for deeper soft-tissue work — tendon, ligament, GI repair, post-surgical recovery. BPC-157's mechanism centers on growth-factor signaling and angiogenesis at injury sites; it is a tissue-repair specialist rather than a skin/hair compound.
Yes — GHK-Cu + BPC-157 is a recognized soft-tissue / connective-tissue stack. GHK-Cu addresses the ECM and skin layer; BPC-157 addresses deeper structural repair. See the BPC-157 + GHK-Cu stack guide for cadence.
They stack → See our full GHK-Cu + BPC-157 stack guide for cadence and side-effect notes.
Peptide Protocol schedules doses, calculates reconstitution, and logs side effects for both — on iPhone, free to download.
See the app →Depth. GHK-Cu stays near the surface and signals ECM/skin remodeling; BPC-157 drives angiogenesis and growth-factor signaling deeper in the tissue.
Yes — GHK-Cu + BPC-157 is a recognized soft-tissue / connective-tissue stack. GHK-Cu addresses the ECM and skin layer; BPC-157 addresses deeper structural repair. See the BPC-157 + GHK-Cu stack guide for cadence.
These target different layers. GHK-Cu is surface-focused: skin, hair, extracellular matrix. BPC-157 is deep-tissue: tendon, ligament, gut. Many users run both, and they appear together in healing stacks.
Pick GHK-Cu for surface-tissue goals — skin quality, hair follicle support, wound healing at or near the skin surface, hair-line topical protocols. GHK-Cu also has the best evidence for gene-expression modulation related to regenerative signaling.
Pick BPC-157 for deeper soft-tissue work — tendon, ligament, GI repair, post-surgical recovery. BPC-157's mechanism centers on growth-factor signaling and angiogenesis at injury sites; it is a tissue-repair specialist rather than a skin/hair compound.
GHK-Cu: Used in cosmetic formulations (topical). Not FDA approved as an injectable drug. — BPC-157: Not FDA approved. Research use only in the US. Removed from FDA 503A bulks list in 2023.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.